Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - Elsevier
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects mediated by …
被引用次数：40 相关文章
[HTML] nih.gov

[HTML][HTML] Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - ncbi.nlm.nih.gov
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects mediated by …

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - … Oncology: Journal of …, 2021 - europepmc.org
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects mediated by …

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - inis.iaea.org
Nrf2 activation putatively mediates clinical benefits of low-..|INIS IAEA NUCLEUS Sign In Sign
In Register Help 50+ years of INIS International Nuclear Information System International …

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo… - … : journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5-1.0 Gy) to (1) beneficial subcellular effects mediated by …
[PDF] academia.edu

[PDF][PDF] Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - academia.edu
abstract Novel mechanistic insights are discussed herein that link a single, nontoxic, low-
dose radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects …

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - thegreenjournal.com
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects mediated by …
[PDF] academia.edu

[PDF][PDF] Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo, R Kapoor… - Radiotherapy and …, 2021 - academia.edu
abstract Novel mechanistic insights are discussed herein that link a single, nontoxic, low-
dose radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects …

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel …

EJ Calabrese, WJ Kozumbo… - … : journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose
radiotherapy (LDRT) treatment (0.5-1.0 Gy) to (1) beneficial subcellular effects mediated by …